Irving, TXNCT06625671Now EnrollingIRB Ready

Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus Clinical Trial in Irving, TX

Access cutting-edge systemic lupus erythematosus (sle) or cutaneous lupus erythematosus treatment through this clinical trial at a research site in Irving. Study-provided care at no cost to qualified participants.

Sponsored by DualityBio Inc.

Quick Self-Assessment

See if you qualify for this Irving location

Preparing your pre-screening questions…

Expert Care in Irving

Access systemic lupus erythematosus (sle) or cutaneous lupus erythematosus specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related systemic lupus erythematosus (sle) or cutaneous lupus erythematosus treatment provided free

Apply for This Irving Location

Check if you qualify for this systemic lupus erythematosus (sle) or cutaneous lupus erythematosus clinical trial in Irving, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Irving

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Irving site if eligible
  4. 4Begin participation

About This Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus Study in Irving

A Phase 1/2a Study of DB-2304 in Healthy Participants and Participants with Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus

Sponsor: DualityBio Inc.

Who Can Participate

Inclusion Criteria

Participants who fully understand the purpose, nature, method, and potential adverse reactions of the study and voluntarily sign the informed consent form (ICF) and agree to participate.
Healthy male or female participants; 18 to 55 years of age (both inclusive) on the day of signing ICF; meet the body mass index (BMI) criteria.
Based on the investigator assessment, there are no abnormal findings or findings with clinical significance from the medical history consultation, physical examination, vital signs assessment, clinical laboratory tests, and 12-lead ECG.
Female participants of childbearing potential or male participants agree to use highly effective contraception during the study.
Participants who are willing and able to comply with the prescribed protocol treatment and evaluations Inclusion Criteria (Part B):
Participants who fully understand the purpose, nature, method, and potential adverse reactions of the study and voluntarily sign the informed consent form (ICF) and agree to participate.
Participants who are willing and able to comply with the prescribed protocol treatment and evaluations.
Male or female participants, 18 to 70 years of age (both inclusive) on the day of signing ICF.
Currently receiving a stable SLE/CLE treatment regimen of any medication for a period of at least 1 month prior to randomization. For SLE： 4. Meet the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for SLE. 5\. History or presence at Screening of positive antinuclear antibodies (ANA) or anti-double-stranded DNA (anti-dsDNA) antibodies. 6\. At screening have active lupus skin disease defined by the SELENA-SLEDAI at screening and randomization. For CLE： 8. Must have diagnosis of CLE that has been histologically confirmed, with or without systemic LE manifestations. 9.Must have active CLE despite an adequate trial of conventional therapies.

Exclusion Criteria

Evidence or history of clinically significant diseases.
History of herpes zoster (shingles) or recurrent herpes simplex (e.g., oral cold sores or gen-ital sores).
Any active or suspected bacterial, viral, fungal, or parasitic infection within 30 days prior to dosing.
History of sensitivity to any ingredients of DB-2304.
Participants who have undergone surgery within the past 3 months or have plans for sur-gery during the study. Exclusion Criteria (Part B):
Have active lupus nephritis or moderate-to-severe or chronic kidney disease
Have active neuropsychiatric SLE within 8 weeks prior to screening
Any active skin conditions or active arthritis other than SLE that may interfere with skin or arthritis assessments (e.g., psoriasis, non-LE skin lesions, non-LE alopecia areata, drug-induced lupus, rheumatoid arthritis) at screening.
History of, or ongoing, malignant disease, including solid tumors and hematologic malignancies with the exception of basal cell carcinomas and squamous cell carcinomas and carcinoma in situ of the cervix that have been completely excised and considered cured \>2 years prior to Screening.
Known history of a primary immunodeficiency (e.g., common variable immunodeficiency syndrome), splenectomy, or any underlying condition that predisposes the participant to infection. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Irving?

Yes, this clinical trial (NCT06625671) has an active research site in Irving, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Systemic Lupus Erythematosus (SLE) or Cutaneous Lupus Erythematosus Treatment Options in Irving, TX

If you're searching for systemic lupus erythematosus (sle) or cutaneous lupus erythematosus treatment options in Irving, TX, this clinical trial (NCT06625671) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Irving research site is actively enrolling participants for this clinical trial. You'll receive care from experienced systemic lupus erythematosus (sle) or cutaneous lupus erythematosus specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all systemic lupus erythematosus (sle) or cutaneous lupus erythematosus clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Irving, TX

See all heart attack clinical trials recruiting in Irving — not just this study.

Browse Heart Attack Trials in Irving →

Browse More Trials by Condition

Heart Attack TrialsLupus TrialsInterstitial Cystitis TrialsSystemic Lupus Erythematosus TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Irving?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Irving, TX